levodopa/carbidopa (CP-012) / BDD Pharma, Bukwang Pharma - LARVOL DELTA

Subsidiary Contera Pharma enters Phase 2 clinical trial (Maeil Business Newpaper) - "Contera Pharma, a subsidiary of Bukwang Pharmaceuticals, plans to complete its Phase 2 clinical trial plan (IND) application to the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) during the first half of the year for the treatment of Parkinson's disease morning insomnia."

IND • New P2 trial • Parkinson's Disease

Quality of life with continuous subcutaneous levodopa/carbidopa infusion: Exploratory findings from the ND0612 BeyoND study (PSG 2023) - "This open-label study provides preliminary support for the 12-month efficacy of treatment with ND0612 in improving quality of life and global clinical status in PwP experiencing motor fluctuations."

Clinical

Management of Dyskinesia and Advances in Treatment of Parkinson’s Disease : Episode 1: Treatment Options for Parkinson Disease (NeurologyLive) - "Dr William G. Ondo provides an overview of available treatments and pharmacokinetic properties of different drugs for Parkinson Disease....Daniel E. Kremens, MD, JD: Hello and welcome to this NeurologyLive Peer Exchange titled, 'Management of Dyskinesia and Advances in Treatment of Parkinson Disease.' I’m your host, Dr Daniel Kremens...And Dr Fernando Pagan...."

Video